Northwest Biotherapeutics Cifra de afaceri pe acțiune (KUV) 2024

Ce face Northwest Biotherapeutics?

Northwest Biotherapeutics Inc is a biotherapy company specializing in immunotherapy and targeted therapy for the treatment of cancer. The company was founded in 1996 and is based in Bethesda, Maryland, USA. The company started as a startup founded by Dr. Alton Boynton, a former Assistant Professor at Georgetown University School of Medicine and an experienced cancer researcher. Recognizing the potential of immunotherapy for the treatment of cancer, Boynton founded the company with the goal of developing new immunotherapy products. In the early 2000s, the company made significant progress. It received FDA approval for a Phase I clinical trial of its first immunotherapy product, DCVax-L, for the treatment of glioblastoma, a type of brain tumor. The company also expanded its presence in Europe and established a subsidiary in the UK. In 2010, the company conducted a successful Phase II trial of DCVax-L and received Fast Track designation from the US Food and Drug Administration (FDA). In 2012, the company was listed on the NASDAQ Capital Market (NASDAQ: NWBO). The business model of Northwest Biotherapeutics Inc is based on the development and commercialization of immunotherapy products for the treatment of cancer. It focuses on developing personalized immunotherapy tailored to the biological characteristics of individual patients. This approach allows the company to develop targeted products that aim at specific types of cancer. Northwest Biotherapeutics Inc has a partnership with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany to support its product development. The partnership enables the use of state-of-the-art technologies for the manufacturing and characterization of cell therapies and allows the company to improve its immunotherapy products. The main product of Northwest Biotherapeutics Inc is DCVax-L, a personalized immunotherapy for the treatment of glioblastoma. DCVax-L is a cell-based therapy that uses the patient's dendritic cells to activate the immune system and fight against cancer. DCVax-L has been studied in Phase I and Phase II clinical trials in both the US and Europe. The company is also developing other immunotherapy products, including DCVax-Direct, a therapy for direct injection of dendritic cells into tumors. The company is also working on the development of DCVax-Prostate, a personalized immunotherapy for the treatment of prostate cancer. In addition to its research and development work, the company collaborates closely with patient organizations, scientists, and physicians to raise awareness of immunotherapy and personalized medicine. It also works with regulatory authorities and healthcare systems to facilitate access to its immunotherapy products. In conclusion, Northwest Biotherapeutics Inc is an innovative biotherapy company specializing in the development of personalized immunotherapy products for the treatment of cancer. With its focus on targeted therapy, the company has the potential to advance the field of immunotherapy and improve the quality of life for cancer patients. Northwest Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.